IL204977A0 - Amide inhibitors of voltage-gated sodium channels, compositions comprising the same and uses thereof - Google Patents
Amide inhibitors of voltage-gated sodium channels, compositions comprising the same and uses thereofInfo
- Publication number
- IL204977A0 IL204977A0 IL204977A IL20497710A IL204977A0 IL 204977 A0 IL204977 A0 IL 204977A0 IL 204977 A IL204977 A IL 204977A IL 20497710 A IL20497710 A IL 20497710A IL 204977 A0 IL204977 A0 IL 204977A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- voltage
- same
- sodium channels
- gated sodium
- Prior art date
Links
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 title 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97929207P | 2007-10-11 | 2007-10-11 | |
| PCT/US2008/079544 WO2009049181A1 (en) | 2007-10-11 | 2008-10-10 | Amides useful as inhibitors of voltage-gated sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL204977A0 true IL204977A0 (en) | 2010-11-30 |
Family
ID=40373424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL204977A IL204977A0 (en) | 2007-10-11 | 2010-04-08 | Amide inhibitors of voltage-gated sodium channels, compositions comprising the same and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8389734B2 (enExample) |
| EP (1) | EP2212292B1 (enExample) |
| JP (1) | JP5436434B2 (enExample) |
| KR (1) | KR20100066583A (enExample) |
| CN (1) | CN101855210A (enExample) |
| AU (1) | AU2008310661A1 (enExample) |
| CA (1) | CA2701766A1 (enExample) |
| IL (1) | IL204977A0 (enExample) |
| MX (1) | MX2010003864A (enExample) |
| NZ (1) | NZ584474A (enExample) |
| RU (1) | RU2010118481A (enExample) |
| WO (1) | WO2009049181A1 (enExample) |
| ZA (1) | ZA201002471B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109112126B (zh) * | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| JP2013532184A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| JP2013536165A (ja) | 2010-07-12 | 2013-09-19 | ファイザー・リミテッド | 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体 |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| EP2655330B1 (en) * | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substituted pyridines as sodium channel blockers |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| RU2683788C2 (ru) | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| RS56015B1 (sr) | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
| CA2898653C (en) * | 2013-01-31 | 2021-09-28 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| UA119147C2 (uk) * | 2013-07-19 | 2019-05-10 | Вертекс Фармасьютікалз Інкорпорейтед | Сульфонаміди як модулятори натрієвих каналів |
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| EP3134729A1 (en) | 2014-04-22 | 2017-03-01 | Q-State Biosciences, Inc. | Analysis of compounds for pain and sensory disorders |
| US10048275B2 (en) | 2015-03-13 | 2018-08-14 | Q-State Biosciences, Inc. | Cardiotoxicity screening methods |
| EP3298448B1 (en) | 2015-05-21 | 2024-09-04 | President and Fellows of Harvard College | Optogenetics microscope |
| NZ742038A (en) | 2015-10-07 | 2019-08-30 | Univ Arizona | Crmp2 sumoylation inhibitors and uses thereof |
| CA3030551C (en) * | 2016-07-07 | 2025-05-06 | Corteva Agriscience Llc | PROCESSES FOR PREPARATION OF 4-ALCOXY-3-(ACYL OR ALKYL)OXYPICOLINAMIDES |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| CA3105657A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| CN110885328B (zh) * | 2018-09-10 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| US12344595B2 (en) | 2018-11-02 | 2025-07-01 | Merck Sharp & Dohme Llc | 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors |
| JP7288051B2 (ja) | 2018-11-02 | 2023-06-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類 |
| WO2020146682A1 (en) * | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| BR112022004495A8 (pt) * | 2019-09-12 | 2023-04-18 | Jiangxi Jemincare Group Co Ltd | Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| CN113045487B (zh) * | 2019-12-27 | 2025-01-17 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| US12516046B2 (en) | 2020-06-17 | 2026-01-06 | Merck Sharp & Dohme Llc | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors |
| GEP20257795B (en) | 2021-05-07 | 2025-09-25 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| TW202317520A (zh) | 2021-06-15 | 2023-05-01 | 德商歌林達有限公司 | 經取代之吡唑醯胺 |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| EP4570788A1 (en) | 2022-08-12 | 2025-06-18 | Guangzhou Fermion Technology Co., Ltd. | Compound as voltage-gated sodium channel inhibitor |
| EP4385979A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Multicyclic inhibitors of nav1.8 |
| EP4385984A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Pyridine-n-oxides as inhibitors of nav1.8 |
| AR131345A1 (es) | 2022-12-14 | 2025-03-12 | Gruenenthal Gmbh | SULFOXIMINAS COMO INHIBIDORES DE NaV1.8 |
| EP4385980A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Indazoles as inhibitors of nav1.8 |
| CN118324743A (zh) * | 2023-04-19 | 2024-07-12 | 中国科学院上海药物研究所 | Nav1.8抑制剂及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE568114A (enExample) * | 1957-05-29 | 1900-01-01 | ||
| ES482591A1 (es) | 1978-07-20 | 1980-04-01 | Basf Ag | Procedimiento para la obtencion de n-arilsulfonilpirroles. |
| US4228449A (en) * | 1978-12-26 | 1980-10-14 | Hughes Aircraft Company | Semiconductor diode array liquid crystal device |
| US6620849B2 (en) * | 2000-07-26 | 2003-09-16 | Icafen, Inc. | Potassium channel inhibitors |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| WO2003037274A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004106324A1 (en) | 2003-05-27 | 2004-12-09 | E.I. Dupont De Nemours And Company | Azolecarboxamide herbicides |
| US7585878B2 (en) * | 2003-06-12 | 2009-09-08 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| EP1673357A2 (en) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| EP2004596A2 (en) * | 2006-04-11 | 2008-12-24 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| US8383734B2 (en) * | 2006-07-17 | 2013-02-26 | Syracuse University | Multi-solution bone cements and methods of making the same |
-
2008
- 2008-10-10 WO PCT/US2008/079544 patent/WO2009049181A1/en not_active Ceased
- 2008-10-10 NZ NZ584474A patent/NZ584474A/en not_active IP Right Cessation
- 2008-10-10 MX MX2010003864A patent/MX2010003864A/es not_active Application Discontinuation
- 2008-10-10 KR KR1020107010372A patent/KR20100066583A/ko not_active Withdrawn
- 2008-10-10 RU RU2010118481/04A patent/RU2010118481A/ru not_active Application Discontinuation
- 2008-10-10 EP EP08837614A patent/EP2212292B1/en active Active
- 2008-10-10 CA CA2701766A patent/CA2701766A1/en not_active Abandoned
- 2008-10-10 US US12/249,251 patent/US8389734B2/en active Active
- 2008-10-10 AU AU2008310661A patent/AU2008310661A1/en not_active Abandoned
- 2008-10-10 JP JP2010529092A patent/JP5436434B2/ja not_active Expired - Fee Related
- 2008-10-10 CN CN200880115687A patent/CN101855210A/zh active Pending
-
2010
- 2010-04-08 IL IL204977A patent/IL204977A0/en unknown
- 2010-04-08 ZA ZA2010/02471A patent/ZA201002471B/en unknown
-
2013
- 2013-01-23 US US13/747,716 patent/US8865771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010118481A (ru) | 2011-11-20 |
| NZ584474A (en) | 2012-06-29 |
| US20130231370A1 (en) | 2013-09-05 |
| US20090118333A1 (en) | 2009-05-07 |
| US8865771B2 (en) | 2014-10-21 |
| US8389734B2 (en) | 2013-03-05 |
| EP2212292A1 (en) | 2010-08-04 |
| KR20100066583A (ko) | 2010-06-17 |
| CA2701766A1 (en) | 2009-04-16 |
| CN101855210A (zh) | 2010-10-06 |
| EP2212292B1 (en) | 2012-12-05 |
| JP5436434B2 (ja) | 2014-03-05 |
| AU2008310661A1 (en) | 2009-04-16 |
| ZA201002471B (en) | 2011-06-29 |
| MX2010003864A (es) | 2010-06-01 |
| WO2009049181A1 (en) | 2009-04-16 |
| JP2011500599A (ja) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL204977A0 (en) | Amide inhibitors of voltage-gated sodium channels, compositions comprising the same and uses thereof | |
| IL204978A0 (en) | Aryl amide inhibitors of voltage-gated sodium channels, compositions conprising the same and uses thereof | |
| ZA200806842B (en) | Imidazole-based compounds,compositions comprising them and methods of their use | |
| IL204442A (en) | Inhibitors of atpase-0fif, medicinal preparations containing them and their use | |
| IL197161A (en) | Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them | |
| IL208180A0 (en) | Central nervous system-active amide compounds, compositions comprising the same and uses thereof | |
| IL230759A0 (en) | Converted acyl anilide, the pharmaceutical composition containing it and its uses | |
| LT2963031T (lt) | Tetrahidrokanabinolio provaistai, provaistus apimančios tetrahidrokanabinolio kompozicijos ir jų panaudojimo būdai | |
| IL201865A0 (en) | Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof | |
| IL183666A0 (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
| IL212836A0 (en) | Azaquinolinone derivatives, compositions comprising the same and uses thereof | |
| EP2202228A4 (en) | AMIDE COMPOUNDS AND THEIR USE | |
| IL202038A0 (en) | Rna antagonist compounds, compositions comprising the same and uses thereof | |
| IL212278A0 (en) | Morpholinopurine derivatives, compositions comprising the same and uses thereof | |
| IL207372A0 (en) | Phenylpyrrole derivatives, compositions comprising the same and uses thereof | |
| IL200387A0 (en) | Heterocylic compounds, compositions comprising them and methods of their use | |
| IL212906A0 (en) | Triazolothiadiazole inhibitor compounds, compositions comprising the same and uses thereore | |
| IL205489A (en) | Affluent compounds, their combinations with HIV inhibitors, preparations and products containing them and their uses | |
| IL215153A0 (en) | Amide derivative compounds, compositions comprising the same and uses there of | |
| IL207639A0 (en) | Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof | |
| GB0819432D0 (en) | Compound, composition and use | |
| IL217928A0 (en) | Amide derivatives, compositions comprising the same and uses thereof | |
| IL207423A0 (en) | Amide derivative and pharmaceutical composition containing the same | |
| IL200795A0 (en) | Prodrug compounds of (+)3-hydroxymorphinan, compositions comprising the same and use thereof | |
| GB0715428D0 (en) | Compositions and uses thereof |